Catalent Strengthens And Expands Talent In Operations, Quality And Innovation




Catalent Strengthens and Expands Talent in Operations, Quality and Innovation

Date: 12/09/2010

Somerset, NJ, December 9, 2010 — Catalent Pharma Solutions continues to invest in employee talent to accelerate their efforts in operational excellence, quality and innovation with the recent hires of Scott Neilson, Vice President of Operations Development with over 25 years of multi-functional, global experience; Elaine Dymond, Vice President of Quality with over 20 years of extensive GMP and managerial experience; Ronald Overhiser, Vice President of Innovation Operations with 20 years of R&D and Commercial Operations experience; and Evjatar Cohen, Vice President of Portfolio Management with 15 years of pharmaceutical experience in project management, quality assurance and R&D.

Scott Neilson has been appointed Vice President of Operations Development for Catalent’s sterile facility in Woodstock, IL. Mr. Neilson will be responsible for leading and executing Catalent’s growth and investment plan for their Blow-Fill-Seal business. He joins Catalent as an accomplished leader with over 25 years of multi-functional, global experience in all phases of the drug development and manufacturing cycle. Most recently, he was the Chief Operating Officer at AAI Pharma, Inc. Mr. Neilson also held senior level leadership roles at MDS Pharma Services, Laboratory Corporation of America, Covance, and SmithKline Beecham. He has a B.S. and an M.B.A. from Lehigh University and an M.S. in Organizational Development from American University.

 Elaine Dymond has been appointed Vice President of Quality and will be responsible for quality and regulatory leadership for Catalent’s softgel and modified release technologies in Europe, Japan and Australia. Ms. Dymond has over 20 years of experience with extensive GMP and managerial experience through management and technical roles within Quality, Compliance, Validation and Quality Control in sterile, biological and solid dosage forms. She has worked at the UK National Health Service, The Wellcome Foundation/Glaxo Wellcome, GlaxoSmithKline, Sanofi-Aventis, and most recently at Merck/Schering-Plough as the Head of Quality, UK. Ms. Dymond is a registered Qualified Person and has held the post of QP Assessor in the UK on behalf of the Society of Biology for more than five years. She has a degree in Microbiology from Bristol West University in the UK and holds an M.Sc. degree in Biomedics from Surrey/Open University. She will be based in Catalent’s Swindon, UK facility.
  

Ronald Overhiser has been appointed Vice President of Innovation Operations. Mr. Overhiser will drive Catalent’s global operations for innovation. He has 20 years of experience in healthcare including leadership roles across both Research and Development and Commercial Organizations. Most recently, Mr. Overhiser led the Research and Development Operations for GE Healthcare Medical Diagnostics where he was responsible for driving operational rigor and efficiency across the R&D organization. He has considerable experience optimizing resources, leading process improvement projects, and partnering with multiple teams to drive results. Mr. Overhiser has an M.B.A. from the University of Michigan and has received his B.S. from the University of Notre Dame. Mr. Overhiser will be based in Somerset, NJ.
  

Evjatar Cohen has been appointed Vice President of Global Portfolio Management. He will manage Catalent’s Innovation portfolio to ensure new product and technology pipeline is balanced and driving growth. Mr. Cohen brings 15 years of pharmaceutical experience to Catalent, with prior roles in Project Management, Quality Assurance, and Research and Development. Most recently, he was Director of Legal Affairs at Teva Pharmaceuticals where he implemented project and portfolio management best practices, including an IP risk assessment for an R&D pipeline of over 1,000 products. Mr. Cohen has an M.B.A. in Pharmaceutical Management, a M.S. in Biotechnology and Food Science from Drexel University, and a B.S. in Chemistry from Hebrew University. Mr. Cohen will be based in Somerset, NJ.

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 29 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit  www.catalent.com .

more products. better treatments. reliably supplied.™